Results 121 to 130 of about 9,966 (258)
A systematic analysis and data mining of opioid-related adverse events submitted to the FAERS database [PDF]
Huyen Le +8 more
openalex +1 more source
Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database
Objective This research aimed to assess the safety of pegvaliase through analyzed the data from the FAERS database, thus providing a theoretical foundation for the rational and safe application of pegvaliase in clinical settings.
Luyao Xu +5 more
doaj +1 more source
Analysis and mining of brodalumab adverse events based on FAERS database
The aim of this study is to evaluate the real-world safety of brodalumab by analyzing adverse events (AEs) associated with the drug. The AE reports related to brodalumab from the FAERS database from 2017 Q1 to 2023 Q4 were collected. Subsequently, we employed four disproportionality analysis methods to identify positive signals among AEs associated ...
Yue Wan +5 more
openaire +2 more sources
Foundation for Anesthesia Education and Research (FAER) [PDF]
F Busoni Foundation +4 more
openalex +1 more source
Journal of Cosmetic Dermatology, Volume 24, Issue 10, October 2025.
Benjamin Xi En Ho +2 more
wiley +1 more source
ObjectiveHypertension is a leading global risk factor for disability and death. Irbesartan, a potent angiotensin II receptor blocker, requires continuous safety monitoring.
Qian Liu +4 more
doaj +1 more source
Understanding size dependence of phase stability and band gap in CsPbI3 perovskite nanocrystals. [PDF]
Inorganic halide perovskites CsPbX3 (X = Cl, Br, I) have been widely studied as colloidal quantum dots for their excellent optoelectronic properties.
Tan, Liang Z, Yang, Ruo Xi
core
PNS2 EXISTENCE OF NOTORIETY BIAS IN FDA ADVERSE EVENT REPORTING SYSTEM (FAERS) DATABASE AND ITS IMPACT ON SIGNAL STRENGTH [PDF]
N. Ravindra Reddy +5 more
openalex +1 more source
A Real-World Safety Analysis of Upadacitinib Based on FDA Adverse Event Reporting System (FAERS) [PDF]
Yazheng Zhao +5 more
openalex +1 more source

